IMRX

Company Overview — What Does Immuneering Corp Do?

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited. Immuneering Corp (IMRX) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Benjamin J. Zeskind and employs approximately 60 people. With a market capitalization of $345M, IMRX is one of the notable companies in the Healthcare sector.

Immuneering Corp (IMRX) Stock Rating — Reduce (April 2026)

As of April 2026, Immuneering Corp receives a Reduce rating with a composite score of 27.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.IMRX ranks #2,667 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Immuneering Corp ranks #355 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

IMRX Stock Price and 52-Week Range

Immuneering Corp (IMRX) currently trades at $5.52. The stock lost $0.14 (2.5%) in the most recent trading session. The 52-week high for IMRX is $10.08, which means the stock is currently trading -45.2% from its annual peak. The 52-week low is $1.10, putting the stock 401.8% above its annual trough. Recent trading volume was 574K shares, suggesting relatively thin trading activity.

Is IMRX Overvalued or Undervalued? — Valuation Analysis

Immuneering Corp (IMRX) carries a value factor score of 20/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.55x, versus the sector average of 2.75x.

At current multiples, Immuneering Corp trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Immuneering Corp Profitability — ROE, Margins, and Quality Score

Immuneering Corp (IMRX) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -27.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -25.4% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

IMRX Debt, Balance Sheet, and Financial Health

Immuneering Corp has a debt-to-equity ratio of 6.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 17.50x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $228M.

IMRX has a beta of 0.90, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Immuneering Corp is 31/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Immuneering Corp Revenue and Earnings History — Quarterly Trend

In TTM 2026, Immuneering Corp reported revenue of $0 and earnings per share (EPS) of $-1.27. Net income for the quarter was $-59M. Operating income came in at $-61M.

In FY 2025, Immuneering Corp reported revenue of $0 and earnings per share (EPS) of $-1.27. Net income for the quarter was $-56M. Operating income came in at $-59M.

In Q3 2025, Immuneering Corp reported revenue of $0 and earnings per share (EPS) of $-0.38. Net income for the quarter was $-15M. Operating income came in at $-15M.

In Q2 2025, Immuneering Corp reported revenue of $0 and earnings per share (EPS) of $-0.40. Net income for the quarter was $-14M. Operating income came in at $-15M.

Over the past 8 quarters, Immuneering Corp has experienced revenue contraction from $0 to $0. Investors analyzing IMRX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

IMRX Dividend Yield and Income Analysis

Immuneering Corp (IMRX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

IMRX Momentum and Technical Analysis Profile

Immuneering Corp (IMRX) has a momentum factor score of 51/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 1/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

IMRX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Immuneering Corp (IMRX) ranks #355 out of 838 stocks based on the Blank Capital composite score. This places IMRX in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing IMRX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full IMRX vs S&P 500 (SPY) comparison to assess how Immuneering Corp stacks up against the broader market across all factor dimensions.

IMRX Next Earnings Date

No upcoming earnings date has been announced for Immuneering Corp (IMRX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy IMRX? — Investment Thesis Summary

The quantitative profile for Immuneering Corp suggests caution. The quality score of 20/100 flags below-average profitability. The value score of 20/100 indicates premium valuation. High volatility (stability score 31/100) increases portfolio risk.

In summary, Immuneering Corp (IMRX) earns a Reduce rating with a composite score of 27.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on IMRX stock.

Related Resources for IMRX Investors

Explore more research and tools: IMRX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare IMRX head-to-head with peers: IMRX vs AZN, IMRX vs SLGL, IMRX vs VMD.